<DOC>
	<DOCNO>NCT00004939</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess efficacy 3,4-diaminopyridine patient stable chronic demyelinate polyneuropathy .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study 3,4-Diaminopyridine Demyelinating Polyneuropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients randomly assign oral 3,4-diaminopyridine ( 3,4-DAP ) placebo administer 4 day . After washout least 5 day , patient cross alternate therapy 4 day .</detailed_description>
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Clinical diagnosis demyelinate neuropathy , i.e . : Hereditary motor sensory neuropathy type I Chronic inflammatory demyelinate polyneuropathy meeting American Academy Neurology AIDS Task Force criterion Multifocal motor neuropathy conduction block Clinically stable least 6 month prior entry Prior/Concurrent Therapy At least 6 month since change immunosuppressive dose Patient Characteristics Age : 20 80 Hepatic : No predisposition hepatic disease Renal : No predisposition renal disease Cardiovascular : No predisposition cardiac disease Other : No medical condition affect neuropathy study evaluation No predisposition seizure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>demyelinate neuropathy</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>